echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > J Cereb Blood Flow Metab: T2 relaxation time of normal white matter in patients with cerebral small vessel disease is related to cognitive status

    J Cereb Blood Flow Metab: T2 relaxation time of normal white matter in patients with cerebral small vessel disease is related to cognitive status

    • Last Update: 2021-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cerebral small vascular disease (SVD) is one of the important causes of ischemic stroke, as well as the main cause of vascular cognitive dysfunction and vascular dementia
    .
    Among the imaging manifestations of SVD on conventional magnetic resonance imaging (MRI) data, different degrees of white matter hyperintensity (WMH) observed on T2-weighted and fluid attenuation inversion recovery (FLAIR) images are usually the main manifestations


    .


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.